Sie suchten nach: substudy (Englisch - Maltesisch)

substudy
arrow

adherence substudy
studju sekondarju tal-aderenza

plato genetic substudy
fergħa tal-istudju ġenetiku plato

increase in sofosbuvir exposure observed in the pharmacokinetic substudy is not clinically relevant.
Żieda fl-esponiment ta’ sofosbuvir osservat fis-sottostudju farmakokinetiku mhux klinikament rilevanti.

the safety profile was generally similar to the adverse event monitoring substudy of the sps.
il-profil ta’ sigurtà kien jixbah b’mod ġenerali dak tas-sottostudju ta’ monitoraġġ ta’ avvenimenti avversi tal-sps.

the results of this substudy suggested that the exposure to the bioactive metabolites (e.g.
ir-riżultati ta’ dan is-sottostudju jissuġġerixxu li l-esponiment għall-metaboliti bioattivi (eż.

endoscopic appearance of the mucosa was evaluated in 252 patients with eligible baseline endoscopic disease activity in a substudy.
id-dehra endoskopika tal-mukuża ġiet evalwata f’252 pazjent b’attività endoskopika tal-marda eliġibbli fil-linja bażi f’sottostudju.

211 patients from the clinical study in older patients participated in a body composition substudy using dxa body composition analysis.
mitejn u ħdax-il pazjent (211) mill-istudju kliniku ta’ pazjenti akbar fl-età pparteċipaw f’sottostudju ta’ kompożizzjoni tal-ġisem bl-użu tal-analiżi dxa ta’ kompożizzjoni tal-ġisem.

the types of events reported in these patients were generally similar to the subgroup of patients in the adverse event monitoring substudy.
it- tipi ta 'avvenimenti rrapportati f' dawn il- pazjenti kienu ġeneralment simili għal dawk irrappurtati mis- subgrupp ta' pazjenti fis- substudju tal- monitoraġġ tal- każ avvers.

an ophthalmology substudy using specific ophthalmic assessments at specified time points was conducted in 54 patients with nsclc who received crizotinib 250 mg twice daily.
sottostudju oftalmoloġiku bl-użu ta’ evalwazzjonijiet oftalmiċi speċifiċi f’punti ta’ żmien speċifiċi twettaq fuq 54 pazjent b’nsclc li rċivew crizotinib 250 mg darbtejn kuljum.

an ecg substudy using blinded manual ecg measurements was conducted in 52 alk-positive nsclc patients who received crizotinib 250 mg twice daily.
twettaq sottostudju dwar l-ecg bl-użu ta’ kejl manwali blinded tal-ecg fi 52 pazjent b’nsclc pożittiv għall-alk li rċevew crizotinib 250 mg darbtejn kuljum.

in addition 12 paediatric patients were enrolled in an uncontrolled substudy for an overall average duration of 3.1 years and up to 4.4 years.
barra dan, 12-il pazjent pedjatriku oħra ħadu sehem f’sottostudju mhux ikkontrollat għal medja ta’ tul totali ta’ 3.1 snin u sa 4.4 snin.

during the holter substudy in plato, more patients had ventricular pauses >3 seconds with ticagrelor than with clopidogrel during the acute phase of their acs.
waqt il-fergħa tal-istudju holter fi plato, aktar pazjenti kellhom pawżi ventrikulari ta’ >3 sekondi b’ticagrelor milli bi clopidogrel waqt il-fażi akuta tal-acs tagħhom.

in a substudy, a small group of patients who had previously received either tetanus, pneumococcal or influenza vaccinations were found to maintain protective titres after treatment with benlysta.
f’sottostudju, grupp żgħir ta’ pazjenti li qabel kienu rċivew tilqim tat-tetnu, tal-pneumococcus jew tal-influenza instabu li żammew titres protettivi wara kura b’benlysta.

the effect of fablyn on the lipid profile was evaluated in a 3-year substudy of the pearl study; the substudy enrolled 1,014 postmenopausal women.
l-effett ta’ fablyn fuq il-profil tal-lipidi ġie evalwat fi studju ta’ 3 snin li kien jifforma parti mill- istudju pearl; dan l-istudju kien jinvolvi 1014-il mara li diġà għaddew mill-menopawsa.

in other clinical trials evaluating zostavax in subjects 50 years of age or older, including a study of concomitantly administered inactivated influenza vaccine, the safety profile was generally similar to that seen in the adverse event monitoring substudy of the sps.
fi provi kliniċi oħra li jevalwaw zostavax f' suġġetti ta '50 sena jew akbar, inkluż studju ta' għoti fl- istess ħin ta 'vaċċin inattivat kontra l- influwenza, il- profil tas- sigurtà kien ġeneralment simili għal dak li jidher fis- substudju ta' monitoraġġ tal- każ avvers tal- sps.

one hundred and sixty-three (163) patients with virus sensitive to agenerase, at least one other pi, and at least one nrti were included in pro30017 substudy a.
16 mija u tlieta u sittin (163) pazjent b’ virus sensittiv għal agenerase, almenu pi ieħor, u almenu nrti ieħor kienu inklużi fl- istudju sekondarju ta ’ pro30017.